Prostamax

Prostamax is a synthetic tetrapeptide (Lysine-Glutamic acid-Aspartic acid-Proline) developed as a prostate-specific bioregulator. It was derived from Prostatilen, a bovine prostate extract that has been approved and used clinically in Russia for decades to treat benign prostatic hyperplasia (BPH) and chronic prostatitis. Prostamax represents the defined synthetic peptide identified as responsible for Prostatilen's primary therapeutic effects. Research from the Khavinson group suggests Prostamax modulates gene expression in prostatic epithelial and stromal cells, normalizing cell proliferation, reducing inflammation, and supporting the tissue's functional capacity. It has been studied in models of BPH, chronic prostatitis, and age-related prostatic changes. Available in Russia in conjunction with the Prostatilen product line.

Prostamax is proposed to regulate gene expression in prostatic epithelial and stromal cells through direct peptide-DNA interaction. Research suggests it normalizes the expression of genes controlling cell proliferation (reducing hyperplastic signaling), anti-inflammatory cytokines, and prostatic secretory function. In BPH models, Prostamax has been shown to reduce 5-alpha-reductase expression and modulate androgen receptor signaling in prostatic tissue without affecting systemic testosterone levels. Anti-inflammatory effects include reduction of TNF-α, IL-1β, and COX-2 expression in prostatic tissue, particularly relevant for chronic prostatitis. The peptide may also support microcirculation in the prostate gland and improve detrusor-sphincter coordination.